Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

PASADENA, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24arwr&src=ctag” target=”_blank”gt;$arwrlt;/agt;–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to participate in the following upcoming events:

Jefferies 2019 Global Health Care Conference – New York, June
4-7, 2019

June 6, 9:30 a.m. EDT – Vincent Anzalone, CFA, Arrowhead’s vice
president of investor relations, will participate in a fireside chat
presentation with Maury Raycroft, Ph.D., Jefferies research analyst

Science of HBV Cure 2019 – Singapore, June 7-8, 2019

June 8, 2:30 p.m. SGT – Bruce Give, M.D., Arrowhead’s chief
operating officer and head of R&D, will deliver an oral presentation
titled, “RNAi: Pulling Us Toward Finite Therapy”

Alpha-1 National Conference – Orlando, FL, June 21-23, 2019

June 21 – James Hamilton, M.D., Arrowhead’s vice president of
clinical development, will deliver an oral presentation titled, “ARO-AAT
for Liver Disease in Alpha-1 Antitrypsin Deficiency: Progress in
Clinical Development”

A copy of the presentation materials and webcast links, if the
presentation is being webcast, may be accessed on the Events
and Presentations
page under the Investors section of the Arrowhead
website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.

For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform
Act:

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the likelihood and
timing of the receipt of future milestone and licensing fees, the future
success of our scientific studies, our ability to successfully develop
and commercialize drug candidates, the timing for starting and
completing clinical trials, rapid technological change in our markets,
and the enforcement of our intellectual property rights. Our most recent
Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q
discuss some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no obligation
to update or revise forward-looking statements to reflect new events or
circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Contacts

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]
www.lifesciadvisors.com

error: Content is protected !!